Copyright Reports & Markets. All rights reserved.

Global Gene Modifying Immunotherapy for Blood Cancer Market Status and Forecast 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Status and Forecast (2016-2027)
      • 1.3.2 Global Gene Modifying Immunotherapy for Blood Cancer Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Gene Modifying Immunotherapy for Blood Cancer Supply by Company

    • 2.1 Global Gene Modifying Immunotherapy for Blood Cancer Sales Value by Company
    • 2.2 Gene Modifying Immunotherapy for Blood Cancer Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Gene Modifying Immunotherapy for Blood Cancer Market Status by Type

    • 3.1 Gene Modifying Immunotherapy for Blood Cancer Type Introduction
      • 3.1.1 CAR T-cell Therapy
      • 3.1.2 TCR T-cell Therapy
    • 3.2 Global Gene Modifying Immunotherapy for Blood Cancer Market by Type
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Gene Modifying Immunotherapy for Blood Cancer Market Status by Application

    • 4.1 Gene Modifying Immunotherapy for Blood Cancer Segment by Application
      • 4.1.1 Acute Lymphocytic Leukemia
      • 4.1.2 Chronic Lymphocytic Leukemia
      • 4.1.3 B Cell Lymphoma
      • 4.1.4 Multiple Myeloma
      • 4.1.5 Other
    • 4.2 Global Gene Modifying Immunotherapy for Blood Cancer Market by Application
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Gene Modifying Immunotherapy for Blood Cancer Market Status by Region

    • 5.1 Global Gene Modifying Immunotherapy for Blood Cancer Market by Region
    • 5.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Status
    • 5.3 Europe Gene Modifying Immunotherapy for Blood Cancer Market Status
    • 5.4 Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Status
    • 5.5 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Status
    • 5.6 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Status

    6 North America Gene Modifying Immunotherapy for Blood Cancer Market Status

    • 6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Gene Modifying Immunotherapy for Blood Cancer Market Status

    • 7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Status

    • 8.1 Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market Status

    • 9.1 Central & South America Gene Modifying Immunotherapy for Blood Cancer Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Status

    • 10.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Type and by Application

    • 12.1 Global Gene Modifying Immunotherapy for Blood Cancer Sales Value Forecast (2022-2027)
    • 12.2 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Type
    • 12.3 Global Gene Modifying Immunotherapy for Blood Cancer Forecast by Application

    13 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Region/Country

    • 13.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Ziopharm Oncology
      • 14.1.1 Company Information
      • 14.1.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.1.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Novartis
      • 14.2.1 Company Information
      • 14.2.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.2.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Mustang Bio
      • 14.3.1 Company Information
      • 14.3.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.3.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Kite Pharma
      • 14.4.1 Company Information
      • 14.4.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.4.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Juno Therapeutics
      • 14.5.1 Company Information
      • 14.5.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.5.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Celyad
      • 14.6.1 Company Information
      • 14.6.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.6.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Cellectis
      • 14.7.1 Company Information
      • 14.7.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.7.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Bluebird Bio
      • 14.8.1 Company Information
      • 14.8.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.8.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Bellicum Pharmaceuticals
      • 14.9.1 Company Information
      • 14.9.2 Gene Modifying Immunotherapy for Blood Cancer Product Introduction
      • 14.9.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.9.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Gene Modifying Immunotherapy for Blood Cancer market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario.This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Gene Modifying Immunotherapy for Blood Cancer industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Gene Modifying Immunotherapy for Blood Cancer market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Gene Modifying Immunotherapy for Blood Cancer Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Gene Modifying Immunotherapy for Blood Cancer market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Gene Modifying Immunotherapy for Blood Cancer Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Gene Modifying Immunotherapy for Blood Cancer industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profies global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      CAR T-cell Therapy
      TCR T-cell Therapy

      Segmented by Application
      Acute Lymphocytic Leukemia
      Chronic Lymphocytic Leukemia
      B Cell Lymphoma
      Multiple Myeloma
      Other

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Ziopharm Oncology
      Novartis
      Mustang Bio
      Kite Pharma
      Juno Therapeutics
      Celyad
      Cellectis
      Bluebird Bio
      Bellicum Pharmaceuticals
      Buy now